Sanofi重启卵巢癌联合研究项目

2013-07-03 yangtao 生物谷

经过一系列卵巢癌研究的挫折后,制药巨头Sanofi公司决定重新上路,Sanofi公司和法国的Curie Institute签署了一项为期三年的联合研究协议。以共同寻找该疾病的新的药物靶点。两家机构计划对比癌症组织和正常组织的分子异同来确定未来新药的药物靶点所在。 详细英文报道: After a series of setbacks in its hunt for ovarian cance

经过一系列卵巢癌研究的挫折后,制药巨头Sanofi公司决定重新上路,Sanofi公司和法国的Curie Institute签署了一项为期三年的联合研究协议。以共同寻找该疾病的新的药物靶点。两家机构计划对比癌症组织和正常组织的分子异同来确定未来新药的药物靶点所在。

详细英文报道:

After a series of setbacks in its hunt for ovarian cancer drugs, Sanofi ($SNY) has struck a three-year partnership deal with the Curie Institute in France that brings scientists back to the molecular drawing board to find new drug targets for the disease.

The Paris-based drug giant and Curie plan to team up on basic research of ovary tumors. They aim to compare molecular differences between ovarian tumor samples and healthy tissue from the same patients with the hope of identifying targets for future drug development. It often takes more than 10 years from the point of target discovery to completing development of a new drug, so this marks an investment in the future of Sanofi's drug pipeline. It's not disclosing financial details, though.

Sanofi has some incentive to begin a drug hunt from scratch after falling short in clinical trials of compounds against ovarian cancer, which is typically treated with chemotherapy and surgery. The drugmaker slammed the brakes on development of ombrabulin for ovarian cancer after the drug candidate failed to pass muster in an interim review of a midstage study. Sanofi also whiffed in a study of its candidate iniparib in ovarian cancer. And though Zaltrap won approval for colon cancer, Sanofi produced only mixed results in using the drug to combat ovarian tumors.

In the search for new ideas, Sanofi and other large drugmakers have headed back to basic research labs in academia. Just this week AstraZeneca ($AZN), which has suffered from its own R&D setbacks, forged an alliance in oncology with Cancer Research UK. Under the pact with Curie Institute, where 1,200 researchers have built expertise in cancer biology, Sanofi gets access to scientific knowledge and technologies that may not exist inside its own organization.

"We hope this type of long-term collaboration will ultimately open up perspectives for new therapeutic options for women with this disease," stated Dr. Debasish Roychowdhury, head of Sanofi Oncology. "It will combine the accumulated knowledge on ovarian cancer gathered over many years by oncologists and biologists at the Institut Curie with the expertise of researchers from Sanofi's research and product development teams."

Sanofi R&D chief Elias Zerhouni has talked up the importance of his researchers translating discoveries from the lab bench to a patient's bedside, and this collaboration with Curie gives the company a chance to do just that.)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (1)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1656436, encodeId=dd91165643653, content=<a href='/topic/show?id=579a158e5a9' target=_blank style='color:#2F92EE;'>#Sanofi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15875, encryptionId=579a158e5a9, topicName=Sanofi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ece524837860, createdName=lq0309, createdTime=Wed Feb 19 10:03:00 CST 2014, time=2014-02-19, status=1, ipAttribution=)]
    2014-02-19 lq0309

相关资讯

ASCO 2013:新辅助化疗治疗晚期卵巢癌或可替代外科手术

  初诊为晚期卵巢癌使用化疗或一期手术的研究:结果来源于MRC CHORUS临床试验     背景:晚期卵巢癌(OC)的一线治疗方法是接受一期外科手术(PS),其次是铂类为基础的辅助化疗(P-CT)。然而,EORTC55971试验建议新辅助化疗(NACT)也可作为一种可供选择的方法,研究显示它能够增加最佳减瘤率和减少手术并发症,且不影响生存。CHORUKS(CRUK07/009)是第二个探讨卵巢

ASCO 2013:帕唑帕尼维持治疗可改善晚期卵巢癌生存

  2013年美国临床肿瘤学年会公布了一项III期临床试验发现:与口服安慰剂相比,III/IV期卵巢癌患者初始化疗成功后予以口服靶向药物帕唑帕尼(pazopanib Votrient)维持治疗无病生存期平均延长5.6个月。   研究者称,大约70%的晚期卵巢癌患者的肿瘤会复发,然而,迄今尚未明确复发风险的预测因子,所以,维持治疗是必需的。帕唑帕尼是一种口服多靶点酪氨酸激酶抑制剂因子,已被证明可用

Gynecol Oncol:Farletuzumab用于对铂敏感的复发性卵巢癌

  Farletuzumab(一种拮抗叶酸受体α的单克隆抗体)用于对铂敏感的复发性卵巢癌   目的:Farletuzumab是一种人源化单克隆抗体,特异靶向于叶酸受体α,在大多数上皮性卵巢癌中高度表达,而在正常组织中基本不表达。研究人员对farletuzumab单独和联合化疗用于对铂敏感的复发性卵巢癌、输卵管癌以及原发性腹膜癌患者的临床疗效进行了评估。   方法:54名合格受试者每周接受非盲的

朱莉除切除乳腺外,还将切除卵巢以避免癌症发生

        为防止乳腺癌,安吉丽娜·朱莉前不久通过手术切除了自己的乳腺。现在看来,她对自己身体器官的维护之旅还没结束,昨日美国媒体报道,这位六个孩子的妈妈即将切除自己的卵巢,因为根据家族病史,她有50%可能患上卵巢癌。   据英国《每日邮报》报道,好莱坞性感女星安吉丽娜·朱莉因公开自己接受双乳乳腺切除手术的事实而受到广泛关注。本周她登上美国《时代》周刊人物封面,畅谈她的手术及目前自己的身体

CA125及HE4联合检测可用于中国妇女盆腔肿块的罹患卵巢癌风险

  雅培ARCHITECT ROMA(卵巢恶性肿瘤风险评估法则)-“CA125及HE4”联合检测,在术前评估存在盆腔肿块的中国妇女罹患卵巢癌风险,准确性可接近90%。    卵巢癌是女性生殖器官常见的肿瘤之一,发病率仅次于子宫颈癌和子宫体癌列居 第三位。但因其早期缺乏特异性症状以及缺乏有效的筛查手段,70%的病人在首次就诊时已是晚期,治疗大难度、复发率高,5

ASCO 2013:多靶点药物Pazopanib维持治疗延缓晚期卵巢癌复发

    美国临床肿瘤学会(ASCO)2013年年会公布的一项针对晚期卵巢癌妇女的III期临床试验发现:与口服安慰剂相比,患者初始化疗成功后予以口服靶向药物pazopanib (Votrient)的无病生存期平均延长5.6个月。    在发达国家,卵巢癌在导致女性死亡的肿瘤中排第五位。晚期卵巢癌是侵袭性疾病,其治愈率只有20-25%。尽管以手术和放疗